拜耳利伐沙班效果怎么样？

Bayer: How effective is rivaroxaban, a treatment used to prevent venous thrombosis (VTE) in adult patients undergoing elective hip or knee replacement surgery?

The purpose of this study was to compare the clinical efficacy and safety of daily antithrombotic therapy with 20 mg, 10 mg of rivaroxaban, and 100 mg of aspirin for 12 months.

In a randomized, double-blind, controlled study, the clinical trial was divided into 3 groups, the first group of 1107 patients took 20 mg of rivaroxaban, the second group of 1127 patients took 10 mg of rivaroxaban, and the third group of 1131 patients took 100 mg of aspirin, these patients had completed 6 to 12 months of initial anticoagulation therapy.

After 12 months of continuous use, the recurrence rate of venous thrombosis in the aspirin group was 4.4%. The recurrence rates of rivaroxaban 20 mg and 10 mg were significantly lower than those in the aspirin group, which were 1.5% and 1.2% respectively. Comparing the three groups, there were very few patients who experienced severe bleeding after taking the drug, which were 0.3%, 0.4% and 0.5% respectively. There was no statistical difference between the three groups. The clinically relevant non-bleeding events between the 3 groups were 2.7, 2.0, and 1.8 respectively, and there was also no statistical difference.

Conclusion: For patients with venous thrombosis who have completed 6 to 12 months of treatment and need to continue treatment and who are clinically balanced, using rivaroxaban 20 mg or 10 mg as a continuous anticoagulant treatment for venous thromboembolism is more effective than 100 mg aspirin, with a significantly lower recurrence rate than aspirin, and does not increase the incidence of bleeding. The feasibility of low-dose (10 mg) treatment of venous thromboembolism was also confirmed.

Recommended related hot articles: /newsDetail/93967.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.